Differential expression of cerbB3 in naevi and malignant melanomas

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 471-474

  Korabiowska, Monika ^a,b,c   Mirecka, Jadwiga ^b   Brinck, Ulrich ^a   Hoefer, Klaus ^a   Marx, Dagmar ^a   Schauer, Alfred ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Department of Pathology ^*  (Germany)

Author keywords

CerbB3; Inmunohistochemistry; Melanoma; Naevi

Indexed keywords

ONCOPROTEIN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; NEVUS; ONCOGENE C ERB; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEVUS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; SKIN NEOPLASMS;

EID: 0029967804     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA: Isolation and characterization of erbB3 a third member of the erbB/epidermal growth factor receptor family, evidence for overexpression in a subset of human mammary tumours. Biochemistry 86: 9193-9197, 1989.
2. Yonemura Y, Ninomiya J, Tanaka M and Sasaki T: Correlation of cerbB2 protein expression and lymph node status in early gastric cancer Oncology 49 363-367, 1992.
3. Gasparini G, Gullick WJ, Maluta S, Palma PD, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine NR and Bevilacqua P: CerbB3 and cerbB2 protein expression in node negative breast carcinoma, an immunocytochemical study. Eur J Cancer 30: 16-22, 1994.
4. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W and Schauer A: Overexpression of the oncogene cerbB2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gyn Pathol 13: 45-53, 1994.
5. Marx D, Schauer A: Expression of the c-erbB oncoproteins in breast cancer. J Cancer Res Clin Oncol 120 Suppl; 2; 1994.
6. Simpson BJB, Weatherill J, Miller EP, Lessells AM, Langdon SP and Miller WR: CerbB3 protein expression in ovarian tumours. BrJ Cancer 71: 758-762, 1995.
7. Koprowski H, Herlyn M, Balaban G, Parmiter A, Alonzo R and Nowell P: Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 11: 297-302, 1985.
8. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ and Mendelsohn J: Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 46: 4726-4731, 1986.
9. Halaban R: Molecular correlates in the progression of normal melanocytes to melanomas. Semin Cancer Biol 4: 171-181, 1993.
10. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden Cr Gullick WJ: Expression of the cerB3 protein in normal human adult and fetal tissues. Oncogene 7: 1273-1278, 1992.
11. Ueda M, Funasaka Y, Ichihashi Mr and Mishima Y: Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma. Br J Dermatol 130: 320-324, 1994.
12. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A and Ulrich A: Progression of human cutaneous melanoma is associated with loss of expression of c-kit protooncogene receptor. Int J Cancer 52: 197-201, 1992.
13. Kraehn GM, Schartl Mx and Peter RU: Human malignant melanoma, a genetic disease? Cancer 75: 1228-1237, 1995.
14. Soltoff SP, Carraway KI, Prigent SA, Gullick WG and Cantley LC: ErbB3 is involved in activation of phosphatidyloinositol 3-kinase by EGF. Mol Cell Biol 14: 3550-3558, 1994.
15. Kita YA, Barff J, Luo Y, Wen D, Brankow D, Hu S, Liu N, Prigent SA, Gullick WJ and Nicolson M: NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
16. Prigent SAVGullick WJ. Identification of cerbB3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGFR receptor/cerbB3 chimera. EMBO J 13: 2831-2841, 1994.